Back

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - PRO.

14 March 2021 (00:50 - 00:57)
Organised by:
Congress Presentation Part of: Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic? Acute Coronary Syndromes ACVC Premium Access ACVC 2021

About the speaker

Photo
Professor Robert Welsh

Mazankowski Alberta Heart Institute, Edmonton (Canada)

5 More presentations in this session

Presentation thumbnail
Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – PRO.
Professor K. Huber (Vienna, AT)
Slides Video
Presentation thumbnail
Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – CON.
Professor C. Granger (Durham, US)
Slides Video
Presentation thumbnail
Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – Discussion.
Presentation thumbnail
Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - CON.
Professor A. Kastrati (Munich, DE)
Slides Video
Presentation thumbnail
Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - Discussion.

Access the full session

Session thumbnail
Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?
Video

The Event

Event poster

ACVC 2021

14 March 2021 00:50 CET
You may be interested in
thumbnail
Congress Presentation
Prasugrel versus ticagrelor in ST-elevation myocardial infarction, a real-world cohort
25 March 2023
thumbnail
Congress Session
Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter
30 August 2024
thumbnail
Congress Presentation
Is there an inter-manufacturer difference in generic clopidogrel response?
26 August 2022
thumbnail
Congress Presentation
Edoxaban in atrial fibrillation with PCI by ACS or stable CAD presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources